Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A combination of a carrier and a complex comprising a nucleic acid molecule and a charged copolymer of the general formula I

wherein R is an amphiphilic polymer or a homo- or hetero-bifunctional derivative thereof,

and wherein X

i) is an amino acid or an amino acid derivative, a peptide or a peptide derivative or a spermine or a spermidine derivative; or

ii) wherein X is

wherein

a is H or, optionally halogen- or dialkylamino-substituted, $C_1\text{-}C_6$ alkyl; and wherein

b, c and d are the same or different, optionally halogen- or dialkylaminosubstituted, $C_1\text{-}C_6$ alkylene; or

iii) wherein X is



wherein

a is H or, optionally halogen or dialkylamino substituted, C₄-C₆-alkyl,

and wherein

 \underline{a} , b and c are the same or different, optionally halogen- or dialkylaminosubstituted, C_1 - C_6 alkylene; or

iv) wherein X

is a substituted aromatic compound with three functional groupings ${}^{t}W_{1}Y_{1}Z_{1}$, wherein W, Y and Z have the meanings mentioned below;

wherein

W, Y or Z are the same or different groups CO, NH, O or S or a linker grouping capable of reacting with SH, OH, NH or NH₂;

and wherein the effector molecule E

is a cationic or anionic peptide or peptide derivative or a spermine or spermidine derivative or a glycosaminoglycane or a non-peptidic oligo/polycation or -anion; wherein

m and n are independently of each other 0, 1 or 2; wherein

p preferably is 3 to 20; and wherein

1 is 1 to 5.

- 2. (Previously presented) The combination according to claim 1, wherein the amphiphilic polymer is a polyalkylene oxide.
- 3. (Previously presented) The combination according to claim 2, wherein the amphiphilic polymer is a polyalkylene glycol.
- 4. (Previously presented) The combination according to any one of claims 1 to 3, wherein X or E is a charged peptide or peptide derivative.

- 5. (Previously presented) The combination according to claim 1, wherein a ligand for a higher eukaryotic cell is coupled to the copolymer.
- 6. (Previously presented) The combination according to any one of claims 1-3 and 5, wherein the nucleic acid molecule is condensed with an organic polycation or cationic lipid molecule and the complex formed thereby has a charged copolymer of the general formula I bound to its surface via ionic interaction.
- 7. (Previously presented) The combination according to any one of claims 1-3 and 5, containing a therapeutically effective nucleic acid molecule.
- 8. (Previously presented) The combination according to any one of claims 1-3 and 5, wherein the carrier consists of a biologically non-resorbable material.
- 9. (Previously presented) The combination according to any one of claims 1-3 and 5, wherein the carrier consists of a biologically resorbable material.

- 10. (Original) The combination according to claim 9, wherein the biologically resorbable material is collagen.
- 11. (Original) The combination according to claim 10, wherein the carrier is a collagen sponge.
- 12. (Previously presented) The combination according to any one of claims 1-3 and 5, wherein the carrier is a carrier which is obtainable by cross-linkage of a copolymer as defined in claim 1.
- 13. (Previously presented) A method of transferring a nucleic acid molecule into a cell comprising using the combination according to any one of claims 1-3 and 5.
- 14. (Previously presented) A pharmaceutical composition comprising the combination according to any one of claims 1-3 and 5.
 - 15. (Canceled).

16. (New) A kit comprising a carrier and a copolymer or a complex as defined in claim 1.

17. (New) The combination according to claim 1, wherein I is 1.

Thus, the backbone for the elected species of copolymer has the following

In addition, in each case, E_n has the following structure: